Protalix BioTherapeutics, Inc. Common Stock
$2.69
-$0.01 (-0.37%)
$2.66Day Range$2.71
Key Statistics
Market Cap
$216.74M
Shares Outstanding
80.6M
Primary Exchange
XASE
Currency
USD
Type
CS
IPO Date
Jan 2, 1996
Round Lot
100
Locale
US
Trading Data
Day Open
$2.68
Day High
$2.71
Day Low
$2.66
Volume
1.25M
VWAP
$2.69
Prev Close
$2.70
Transactions
--
Acc. Volume
--
About Protalix BioTherapeutics, Inc. Common Stock
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836226 employees2 UNIVERSITY PLAZA, HACKENSACK, NJ, 07601201-696-9345IPO Jan 2, 1996US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001006281
- Composite FIGI
- BBG000JW08N5
- Share Class FIGI
- BBG001SBVMW4
- Ticker Root
- PLX
- SIC Code
- 2836
About Protalix BioTherapeutics, Inc. Common Stock (PLX) Stock
Protalix BioTherapeutics, Inc. Common Stock (PLX) closed the 2026-09-18 session at $2.69, down 0.37% versus the previous close (-0.01). The stock opened at $2.68 and traded between $2.66 and $2.71 during that session. Session trading volume was 1.2M shares. The volume-weighted average price (VWAP) is $2.69.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Protalix BioTherapeutics, Inc. Common Stock has a market capitalization of $216.7 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. PLX is listed on the XASE exchange. The company employs approximately 226 people. Protalix BioTherapeutics, Inc. Common Stock is headquartered in HACKENSACK, NJ. The recorded listing date is 1996-01-02.
On this page you can find market PLX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.